<http://webisa.webdatacommons.org/389175693>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/prov/436841062>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/389175693> .
<http://webisa.webdatacommons.org/389175693>	<http://www.w3.org/ns/prov#value>	"We aim for the VRFCAT to be used as a reliable tool in clinical trials to measure changes in functional capacity associated with the pro-cognitive effects of novel drugs for schizophrenia, bipolar disorder, Alzheimer's disease and other diseases,??? said Richard Keefe, founder and CEO of NeuroCog Trials." .
<http://webisa.webdatacommons.org/389175693>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<centerwatch.com> .
<http://webisa.webdatacommons.org/prov/341409986>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/389175693> .